Investor Relations

Please see below for a summary of our results and recent presentations.

Results

We are developing a new, unique cancer drug.

Latest data from the BEXMAB trial are a powerful indication of the therapeutic potential of bexmarilimab in hematological malignancies with bexmarilimab well tolerated across the trial and efficacy signals across all patient cohorts (an increasing bexmarilimab dose and in combination with azacitidine as a doublet, and azacitidine + venetoclax as a triplet therapy).

In solid tumors, we have tested the drug in over 200 cancer patients that have no treatment option left and face death. We have shown that the drug is well-tolerated and not toxic like chemotherapy. We have shown that 1 out of 3 patients with gastric cancer, liver cancer, melanoma, bile duct cancer or breast cancer benefit from the drug and that we can stabilize the progression of cancer. These patients live 3 times longer than the patients that do not benefit from the drug.

View our pipeline